Terms: = Lung cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Clinical Outcome
50 results:
1. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.
Liu X; Deng J; Zhang R; Xing J; Wu Y; Chen W; Liang B; Xing D; Xu J; Zhang M
Front Immunol; 2023; 14():1335252. PubMed ID: 38162667
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract] [Full Text] [Related]
3. Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in lung cancer Patients with EGFR/erbb2 Exon 20 Insertion.
Zheng Y; Fu Y; Chen Y; Li Q; Liu T; Ding Z
Curr Oncol; 2023 Nov; 30(11):9929-9939. PubMed ID: 37999141
[TBL] [Abstract] [Full Text] [Related]
4. Genomic Characteristics and the Potential clinical Implications in Oligometastatic Non-Small Cell lung cancer.
Liao R; Chen K; Li J; He H; Yi G; Huang M; Chen R; Shen L; Zhang X; Xu Z; Yang Z; Peng Y
Cancer Res Treat; 2023 Jul; 55(3):814-831. PubMed ID: 36634615
[TBL] [Abstract] [Full Text] [Related]
5. Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes.
Yao Y; Yu Z; Ma Y; Ou Q; Wu X; Lu D; Li X
ESMO Open; 2022 Apr; 7(2):100405. PubMed ID: 35305401
[TBL] [Abstract] [Full Text] [Related]
6. Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma.
Chen S; Fu A; Lu Y; Lu W; Chen Y; Hong S; Zhou S; Xiang T; Zhang Z; Cai Y
BMC Genomics; 2022 Jan; 23(1):55. PubMed ID: 35031014
[TBL] [Abstract] [Full Text] [Related]
7. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract] [Full Text] [Related]
8. clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
Couraud S; Barlesi F; Fontaine-Deraluelle C; Debieuvre D; Merlio JP; Moreau L; Beau-Faller M; Veillon R; Mosser J; Al Freijat F; Bringuier PP; Léna H; Ouafik L; Westeel V; Morel A; Audigier-Valette C; Missy P; Langlais A; Morin F; Souquet PJ; Planchard D;
Eur J Cancer; 2019 Jul; 116():86-97. PubMed ID: 31181537
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell lung cancer.
Fang W; Ma Y; Yin JC; Hong S; Zhou H; Wang A; Wang F; Bao H; Wu X; Yang Y; Huang Y; Zhao H; Shao YW; Zhang L
Clin Cancer Res; 2019 Aug; 25(16):5015-5026. PubMed ID: 31085721
[TBL] [Abstract] [Full Text] [Related]
10. Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces her2 Breast cancer Aggressiveness.
Molina-Crespo Á; Cadete A; Sarrio D; Gámez-Chiachio M; Martinez L; Chao K; Olivera A; Gonella A; Díaz E; Palacios J; Dhal PK; Besev M; Rodríguez-Serrano M; García Bermejo ML; Triviño JC; Cano A; García-Fuentes M; Herzberg O; Torres D; Alonso MJ; Moreno-Bueno G
Clin Cancer Res; 2019 Aug; 25(15):4846-4858. PubMed ID: 31064780
[TBL] [Abstract] [Full Text] [Related]
11. Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell lung cancer.
Phallen J; Leal A; Woodward BD; Forde PM; Naidoo J; Marrone KA; Brahmer JR; Fiksel J; Medina JE; Cristiano S; Palsgrove DN; Gocke CD; Bruhm DC; Keshavarzian P; Adleff V; Weihe E; Anagnostou V; Scharpf RB; Velculescu VE; Husain H
Cancer Res; 2019 Mar; 79(6):1204-1213. PubMed ID: 30573519
[TBL] [Abstract] [Full Text] [Related]
12. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/her2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract] [Full Text] [Related]
13. clinical Significance of Complex Glandular Patterns in lung Adenocarcinoma: Clinicopathologic and Molecular Study in a Large Series of Cases.
Kuang M; Shen X; Yuan C; Hu H; Zhang Y; Pan Y; Cheng C; Zheng D; Cheng L; Zhao Y; Tao X; Li Y; Chen H; Sun Y
Am J Clin Pathol; 2018 May; 150(1):65-73. PubMed ID: 29746612
[TBL] [Abstract] [Full Text] [Related]
14. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
Oh YJ; Park SY; Seo YH
Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674
[TBL] [Abstract] [Full Text] [Related]
15. CD73 Promotes Resistance to her2/erbb2 Antibody Therapy.
Turcotte M; Allard D; Mittal D; Bareche Y; Buisseret L; José V; Pommey S; Delisle V; Loi S; Joensuu H; Kellokumpu-Lehtinen PL; Sotiriou C; Smyth MJ; Stagg J
Cancer Res; 2017 Oct; 77(20):5652-5663. PubMed ID: 28855210
[TBL] [Abstract] [Full Text] [Related]
16. Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.
Koinis F; Voutsina A; Kalikaki A; Koutsopoulos A; Lagoudaki E; Tsakalaki E; Dermitzaki EK; Kontopodis E; Pallis AG; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2018 Feb; 20(2):140-149. PubMed ID: 28631135
[TBL] [Abstract] [Full Text] [Related]
17. Predictive outcomes for her2-enriched cancer Using Growth and Metastasis Signatures Driven By SPARC.
Güttlein LN; Benedetti LG; Fresno C; Spallanzani RG; Mansilla SF; Rotondaro C; Raffo Iraolagoitia XL; Salvatierra E; Bravo AI; Fernández EA; Gottifredi V; Zwirner NW; Llera AS; Podhajcer OL
Mol Cancer Res; 2017 Mar; 15(3):304-316. PubMed ID: 28031408
[TBL] [Abstract] [Full Text] [Related]
18. miR-141-Mediated Regulation of Brain Metastasis From Breast cancer.
Debeb BG; Lacerda L; Anfossi S; Diagaradjane P; Chu K; Bambhroliya A; Huo L; Wei C; Larson RA; Wolfe AR; Xu W; Smith DL; Li L; Ivan C; Allen PK; Wu W; Calin GA; Krishnamurthy S; Zhang XH; Buchholz TA; Ueno NT; Reuben JM; Woodward WA
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27075851
[TBL] [Abstract] [Full Text] [Related]
19. Significance of EGFR signaling pathway genetic alterations in radically resected non-small cell lung cancers from a Polish cohort. One institutional study.
Kowalczuk O; Kozlowski M; Milewski R; Minarowski L; Reszec J
Adv Med Sci; 2015 Sep; 60(2):277-86. PubMed ID: 26118982
[TBL] [Abstract] [Full Text] [Related]
20. Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.
Jamal-Hanjani M; A'Hern R; Birkbak NJ; Gorman P; Grönroos E; Ngang S; Nicola P; Rahman L; Thanopoulou E; Kelly G; Ellis P; Barrett-Lee P; Johnston SR; Bliss J; Roylance R; Swanton C
Ann Oncol; 2015 Jul; 26(7):1340-6. PubMed ID: 26003169
[TBL] [Abstract] [Full Text] [Related]
[Next]
